Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 125   

Articles published

JNJ 125.15 +0.26 (0.21%)
price chart
Johnson & Johnson Offered Woman $1.3 Million To “Keep Quiet” About Talcum ...
Johnson & Johnson is being hit with lawsuits all over the country over the link between their talcum powder and ovarian cancer.
Johnson & Johnson: 1 Dividend Stock to Own Forever
Healthcare and consumer goods companies might not sound as exciting as Internet ones, but in this ultra-low interest rate environment, it could be rewarding to take a look at Johnson & Johnson (NYSE:JNJ) stock. First of all, let's get one thing out of ...
Johnson & Johnson: Patience Finally Beginning To Pay Off  Seeking Alpha
Millie Capital Management buys $1581129 stake in Johnson & Johnson (JNJ)  Trade Calls
Can Big Still Be Beautiful?
For the 56-year-old CEO of Johnson & Johnson, this drizzly morning in May—Analyst Day—offered a chance to put some show behind a tell he had been making for the previous four years, or since he had assumed the reins of the $70-billion-a-year health ...
Two Former Johnson & Johnson Execs Just Got Convicted for Improper Marketing
A federal jury on Wednesday convicted two former top executives at medical device company Acclarent, a unit of drug giant Johnson & Johnson JNJ -0.11% , for improperly marketing a sinus-opening device. The Boston jury found Facteau and Fabian guilty ...
Jury finds former J&J executives guilty of illegal marketing for medical ...  Becker's Hospital Review
Johnson & Johnson subsidiary pays $18 million to U.S. in settlement
WASHINGTON, July 23 (UPI) -- Johnson & Johnson's subsidiary Acclarent, paid $18 million to resolve allegations the company marketed a medical device without FDA approval, which led health care providers to submit false claims to Medicare and other ...
Johnson & Johnson Subsidiary Acclarent Settles Medical Device-Related ...  Tech Times
Johnson & Johnson's Acclarent Unit in $18 Million US Settlement  Wall Street Journal
Johnson & Johnson Unit to Pay $18 Million to Settle False Claims Act Allegations
California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, will pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal healthcare ...
Johnson & Johnson Raises Guidance, Buoyed by Pharma Growth
Johnson & Johnson JNJ 0.21 % on Tuesday raised its guidance for the year again as the health-care giant topped expectations in the latest quarter, helped by growth in its pharmaceutical business.
What to expect from Johnson & Johnson earnings  MarketWatch
Johnson & Johnson Tops 2Q Forecasts Despite Profit Drop  New York Times
Johnson & Johnson: Great Quality, But Stock Has No Margin Of Safety
This piece is in response to Bob Ciura's article where he states that Johnson & Johnson is a quality stock and that it is “cheap”.
3 Important Takeaways From Johnson & Johnson's Second-Quarter Earnings
Johnson & Johnson (NYSE: JNJ) is a healthcare Goliath that operates consumer healthcare, pharmaceuticals, and medical device businesses.
Why I'm Easing Off Johnson & Johnson  Seeking Alpha
Jury Acquits Former Johnson & Johnson Unit Execs of Felony Fraud
Mr. Facteau was the chief executive and Mr. Fabian was vice president of sales at medical-device maker Acclarent, a unit of Johnson & Johnson. In April 2015, a federal grand jury indicted them on criminal charges including conspiring to market a ...
Former execs at J&J division convicted of illegally distributing devices  STAT